Related Experiment Video
Updated: May 6, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
When academia met industry: working toward a needle-free vaccination future in the sunshine state
Arti Medhavy1, Alex Johnston1, Imogen Bermingham2
1Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia.
Abstract:
Located in Brisbane's Northshore riverfront precinct, just meters from the iconic Brisbane River, is the new Vaxxas Biomedical Facility. Dr Imogen Bermingham is a Principal Scientist in the Formulation and Analytical Team at Vaxxas, an Australian biotech company focused on developing a needle-free vaccination technology. Here, we discuss her work at Vaxxas, highlighting the opportunities for translational research within the growing biotech industry landscape in Queensland, Australia. Dr Bermingham also reflects on her transition from academia to industry, leveraging her skill set and expanding her capabilities within the dynamic research environment at Vaxxas.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Microorganisms in Medicine and Therapeutics
Vaccine Production
Vaccines

